BioBehavioral Diagnostics takes in $300,000
BioBehavioral Diagnostics Co., which makes a medical device for attention deficit hyperactivity disorder (ADHD), has raised $300,000 in a sale of $500,000 in securities, according to federal documents.
Though the company did not specify how the money would be used, executive chairman Byron Hewett said at a conference in January that the company plans to start marketing the next generation of its Quotient ADHD system this July, and it plans to more than double its sales force this year. It also plans to develop clinical trials for its Quotient system. The privately held company, headquartered in Plymouth Meeting, Pa., has R&D and customer service operations in Westford. It was founded in 2006.